References
- Kamiya N. The mechanisms of action of antivirals against hepatitis B virus infection. J Antimicrob Chemother 2003; 51: 1085–1089.
- Lok ASF, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus infected patients during lamivudine therapy: Evaluation of performance of Inno-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729–3734.
- Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38: S90–S103.
- Angus P, Vaughan R, Xiong S et al. Resistance to ade-fovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–297.
- Mutimer D. Hepatitis B virus infection: Resistance to antiviral agents. J Clin Virol 2001; 21: 239–242.
- Stuyver II, Locarnini SA, Lok A et al. Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751–757.
- Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the Inno-LiPA HBV DR line probe assay for detection of lamivudine resistant hepatitis B strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 1972–1974.
- Allen MI, Gauthier J, DesLauriers M et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37: 3338–3347.
- Stuyver L, Geyt CV, De Gent et al. Line probe assay for monitoring drug resistance in hepatitis B virus infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702–707.
- Bêatrice S, Christian P, Sinafa SA et al. Evolution of Hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic Hepatitis B. J Infect Dis 2000; 181 (4): 1221–1233.
- Niesters HGM, De Man RA, Pas S, Fries E, Osterhaus AD. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51 (8): 695–699.
- Bozdayi MA, Uzunalimoglu O, Turkyilmaz AR et al. YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003; 10 (4): 256–65.
- Pas S, Fries E, De Man RA, Osterhaus AD, Niesters HGM. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commer-cial assays. J Clin Microbiol 2000; 38: 2897–2901.
- Lindh M, Andersson AS, Gusdal G. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-1293.
- Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 18; 339 (6221): 237-238.
- Pas S, De Man RA, Fries E, Osterhaus AD, Niesters HGM. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamuvidine treatment as determined by reverse hybridization. J Clin Virol 2002; 25: 63–71.
- Niesters HGM, Honkoop P, Haagsma EB et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 1382–1385.
- Zollner B, Petersen J, Puchhammer et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39: 42–50.
- Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38: 315–321.
- Buti M, Cotrina M, Valdes A, Jardi R, Frias FR, Esteban R. Is hepatitis B virus subtype testing useful in predict-ing virological response and resistance to lamivudine. J Hepatol 2002; 36: 445–446.